Investigation of clinical efficacy of Enzalutamide and its predictive factors in CRPC patients

Investigation of clinical efficacy of Enzalutamide and its predictive factors in CRPC patients - Efficacy of Enzalutamide in CRPC patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015996

Enrollment

Registered

2014-12-23

Start date

2014-12-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

castration resistant prostate cancer

Interventions

Treatment with Enzalutamide

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1)CRPC patients undergoing ADT with GnRH antagonists,agonist or bilateral orchiectomy 2) Testosterone levels of less than 50 ng/dL 3) 25% increase in PSA from nadir (and by 2 ng/mL) which is confirmed 4 weeks later 4) ECOG PS 0-2 5) Signed written informed consent

Exclusion criteria

Exclusion criteria: 1) Severe cardiac function disorders, hepatic function disorders, renal function disorders, infectious disease or hematopoietic disorders 2) Hypersensitivity to study medication 3) History of seizure or any condition that may predispose to seizure 4) Age <20 years 5) History of treatment with Enzalutamide, Abiraterone or chemotherapy 6) Patients whom the investigator judges inappropriate for the study

Design outcomes

Primary

Measure	Time frame
SMAC, CBC, serum PSA, cytokines, androgens, Lipid metabolism. Bone markers, QoL assessment PSA-PFS	—

Countries

Japan

Contacts

Public ContactTakeo Kosaka

Keio University School of Medicine Department of Urology

takemduro@gmail.com03-5363-3825

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026